Related references
Note: Only part of the references are listed.Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression
Zu-Yau Lin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2022)
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels
Po-Yao Hsu et al.
CANCER MEDICINE (2022)
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
Min Jin Lee et al.
INVESTIGATIONAL NEW DRUGS (2021)
Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma
Zu-Yau Lin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Evolution of systemic treatment for advanced hepatocellular carcinoma
Tsung-Che Wu et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2021)
Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules
Zu-Yau Lin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2020)
Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment
Zu-Yau Lin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2020)
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
Eavan C. McLoughlin et al.
PHARMACEUTICALS (2020)
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
Elena De Mattia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Prognostic and clinicopathological value of Nanog in hepatocellular carcinoma: A meta-analysis
Chaojie Liang et al.
CLINICA CHIMICA ACTA (2018)
Stem cell fate in cancer growth, progression and therapy resistance
Nikki K. Lytle et al.
NATURE REVIEWS CANCER (2018)
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma
Alexander Solms et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients
Zu-Yau Lin et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways
Yanmin Xu et al.
CANCER LETTERS (2016)
The cancer stem-cell signaling network and resistance to therapy
A. Carnero et al.
CANCER TREATMENT REVIEWS (2016)
Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines
Zu-Yau Lin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2016)
Modulation of Autophagy by Sorafenib: Effects on Treatment Response
Nestor Prieto-Dominguez et al.
FRONTIERS IN PHARMACOLOGY (2016)
Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma
Chun-Chieh Wu et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2015)
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study
Carmen Fucile et al.
MEDICAL ONCOLOGY (2015)
Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
Masahide Fukudo et al.
CLINICAL PHARMACOKINETICS (2014)
Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma
Zu-Yau Lin et al.
LIFE SCIENCES (2013)
Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells
Zu-Yau Lin et al.
BIOMEDICINE & PHARMACOTHERAPY (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
High Versus Low Dosing of Oral Colchicine for Early Acute Gout Flare Twenty-Four-Hour Outcome of the First Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Colchicine Study
Robert A. Terkeltaub et al.
ARTHRITIS AND RHEUMATISM (2010)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique
ZY Lin et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
